secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corvus Pharmaceuticals, Inc. (CRVS)
CIK:        0001626971
Form:       8-K
Filed at:   2024-03-19T23:59:59+00:00
Accession:  0001171843-24-001454
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corvus Q4 net loss $6.7M; soquelitinib Orphan Drug; Phase 3 PTCL trial on track
-------------------------------------------------------------------------------

- Net loss $6.7M in Q4 2023 vs $9.8M Q4 2022; cash $27.1M at Dec 31, 2023.
- Soquelitinib Phase 1/1b: 7 of 21 evaluable PTCL patients had objective responses (4 CR, 3 PR).
- FDA granted Orphan Drug Designation for soquelitinib in T cell lymphoma (Feb 2024).
- Registrational Phase 3 PTCL trial expected to initiate Q3 2024; Phase 1 atopic dermatitis trial Q2 2024.
- Appointed Jeffrey Arcara as Chief Business Officer to lead corporate strategy and business development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626971/000117184324001454/0001171843-24-001454-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626971/000117184324001454/f8k_031924.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-001454

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer